News | Heart Failure | October 09, 2023

TAVR: Less Than One-third of Patients Enter Cardiac Rehab After Heart Procedure

The program is recommended by the Centers for Medicare and Medicaid services for patients who undergo heart valve repair or replacement

The program is recommended by the Centers for Medicare and Medicaid services for patients who undergo heart valve repair or replacement

Image courtesy of JACC


October 9, 2023 — The vast majority of people who have a minimally invasive heart valve replacement procedure do not participate in recommended cardiac rehabilitation, a Michigan Medicine-led study finds.

Researchers used clinical registry and health care claims data from over 3,300 patients who underwent transcatheter aortic valve replacement, or TAVR, in Michigan across 24 hospitals between 2016 and mid-2020, to determine the rate of cardiac rehabilitation participation and the factors associated with its utilization.

Results published in JACC: Advances reveal that just 30.6% of patients who underwent TAVR participated in cardiac rehabilitation within 90 days after discharge.

Patients who were older, more frail, smoked or had a history of common heart rhythm issues, like atrial fibrillation, were less likely to enter cardiac rehab.

Whether a patient participated in the medically supervised exercise and educational program varied substantially across 24 hospitals, ranging from 5 to 60%.

This variation across hospitals persisted despite accounting for differences in the characteristics of the patients treated at these hospitals.

The participation rate for cardiac rehab after TAVR was significantly lower than that for patients who had open-heart surgeries.

Researchers say the difference may be explained by TAVR patients being more frail or medically complex than patients who undergo surgical repair.

Investigators also note that patients may not receive the appropriate education regarding the importance of cardiac rehabilitation after this minimally invasive procedure.

“Cardiac rehabilitation has been shown to improve the quality of life for so many patients after cardiovascular procedures,” said first author Devraj Sukul, M.D., M.Sc., interventional cardiologist at the University of Michigan Health Frankel Cardiovascular Center and clinical assistant professor of internal medicine-cardiology at U-M Medical School.

“We found that the differences in participation between hospitals may be related to differences in the process each hospital takes after a patient undergoes TAVR. It is critical that we identify best practices to promote cardiac rehab participation to improve post-operative outcomes.”

For more information: https://www.uofmhealth.org/


Related Content

News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced ...

Home November 29, 2023
Home
News | Cardiovascular Clinical Studies

November 28, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announces the first patient in the world has been ...

Home November 28, 2023
Home
News | Cardiovascular Clinical Studies

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
News | Cardiovascular Clinical Studies

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
News | Cardiovascular Clinical Studies

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
News | Cardiovascular Clinical Studies

November 6, 2023 — Bristol Myers Squibb announced that research across the company’s cardiovascular franchise will be ...

Home November 06, 2023
Home
News | Cardiovascular Clinical Studies

October 20, 2023 — JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) ...

Home October 20, 2023
Home
Subscribe Now